Richard Douglas, Ph.D.
As an advisor to Red Sky Partners, Richard Douglas works with clients on corporate and business development strategy, therapeutic area and target selection and execution on both in and out licensing efforts. He has extensive experience in therapeutic areas ranging from rare diseases, oncology, and ophthalmology to metabolic and cardiovascular disease. His experience includes a wide range of pharma, biotech, diagnostics and device efforts including work with small molecules, biologics, cell and gene therapies.
Prior to his work with Red Sky, Richard had over 30 years of biotechnology experience. He served as Senior Vice President of Corporate Development and Corporate Officer of Genzyme Corporation and was with Genzyme from 1989 to 2011. As a leader of Genzyme’s Corporate Development team, Richard was involved in numerous acquisitions, licenses, joint ventures, strategic alliances, and was responsible for starting its corporate venture group. From 1982 till its acquisition by Genzyme Corporation in 1989, Richard served in Science and Corporate Development capacities at Integrated Genetics; initially as Manager of Protein Chemistry Research and then as Director of New Product Development.
In addition to his work with Red Sky, Richard is on the Board of Novavax, Inc. and Aldeyra Therapeutics, Inc. He is also Chair of the National Advisory Board of the Technology Transfer Office at the University of Michigan, serves on two translational research oversite committees for the University’s Medical School and is on the Life Science Institute’s Leadership Council.
Richard has a Ph.D. in Biochemistry from the University of California, Berkeley and was a Post-Doctoral Fellow at the California Institute of Technology in Leroy Hood’s lab, and received a BS in Chemistry from the University of Michigan.